Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Glaukos Co. stock logo
GKOS
Glaukos
$96.22
-1.0%
$93.43
$77.10
$163.71
$5.50B0.83696,970 shs829,075 shs
Envista Holdings Co. stock logo
NVST
Envista
$16.73
-0.8%
$16.57
$14.22
$23.00
$2.84B0.972.56 million shs2.06 million shs
Penumbra, Inc. stock logo
PEN
Penumbra
$268.72
+0.7%
$279.68
$148.00
$310.00
$10.41B0.53442,990 shs235,921 shs
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€22.24
-1.6%
€21.72
€16.56
€25.75
$6.74B0.51343,538 shs159,500 shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Glaukos Co. stock logo
GKOS
Glaukos
-1.19%+0.81%+3.83%-23.65%-10.69%
Envista Holdings Co. stock logo
NVST
Envista
-0.63%-8.27%+6.25%-19.95%-10.20%
Penumbra, Inc. stock logo
PEN
Penumbra
+0.68%-4.40%-3.40%-8.14%+35.06%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
-2.07%-7.22%+1.74%+7.39%+14.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Glaukos Co. stock logo
GKOS
Glaukos
4.6012 of 5 stars
4.42.00.04.44.02.50.6
Envista Holdings Co. stock logo
NVST
Envista
4.17 of 5 stars
3.13.00.03.82.90.02.5
Penumbra, Inc. stock logo
PEN
Penumbra
4.6973 of 5 stars
3.44.00.03.73.92.51.9
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
1.3359 of 5 stars
0.01.01.70.03.70.01.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Glaukos Co. stock logo
GKOS
Glaukos
2.75
Moderate Buy$134.6739.95% Upside
Envista Holdings Co. stock logo
NVST
Envista
2.14
Hold$20.0819.98% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.88
Moderate Buy$302.4012.53% Upside
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
2.86
Moderate BuyN/AN/A

Current Analyst Ratings Breakdown

Latest NVST, PEN, STVN, and GKOS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/6/2025
Glaukos Co. stock logo
GKOS
Glaukos
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.00
5/5/2025
Envista Holdings Co. stock logo
NVST
Envista
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$21.00 ➝ $18.00
5/2/2025
Envista Holdings Co. stock logo
NVST
Envista
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$21.00
5/2/2025
Glaukos Co. stock logo
GKOS
Glaukos
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.00
5/1/2025
Glaukos Co. stock logo
GKOS
Glaukos
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$140.00 ➝ $135.00
5/1/2025
Glaukos Co. stock logo
GKOS
Glaukos
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$140.00 ➝ $115.00
5/1/2025
Glaukos Co. stock logo
GKOS
Glaukos
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$176.00 ➝ $115.00
5/1/2025
Glaukos Co. stock logo
GKOS
Glaukos
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$160.00 ➝ $86.00
4/30/2025
Envista Holdings Co. stock logo
NVST
Envista
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$18.00 ➝ $17.00
4/29/2025
Envista Holdings Co. stock logo
NVST
Envista
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$26.00 ➝ $23.00
4/24/2025
Penumbra, Inc. stock logo
PEN
Penumbra
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$320.00 ➝ $330.00
(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Glaukos Co. stock logo
GKOS
Glaukos
$404.52M13.59N/AN/A$9.46 per share10.17
Envista Holdings Co. stock logo
NVST
Envista
$2.50B1.13$1.30 per share12.91$17.04 per share0.98
Penumbra, Inc. stock logo
PEN
Penumbra
$1.24B8.39$2.56 per share105.01$29.88 per share8.99
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
$1.12B5.99€0.93 per share23.97€4.15 per share5.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Glaukos Co. stock logo
GKOS
Glaukos
-$134.66M-$2.37N/AN/AN/A-39.04%-16.53%-10.61%7/30/2025 (Estimated)
Envista Holdings Co. stock logo
NVST
Envista
-$1.12B-$6.53N/A13.831.27-44.56%3.86%2.21%8/6/2025 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$90.95M$1.06790.3553.642.831.17%9.74%7.35%7/29/2025 (Estimated)
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
$157.62M€0.5147.3238.347.1810.47%9.86%5.79%N/A

Latest NVST, PEN, STVN, and GKOS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2025Q1 2025
Envista Holdings Co. stock logo
NVST
Envista
$0.20$0.24+$0.04$0.10$608.17 million$616.90 million
4/30/2025Q1 2025
Glaukos Co. stock logo
GKOS
Glaukos
-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 million
4/23/2025Q1 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.66$0.83+$0.17$1.00$315.72 million$324.14 million
3/6/2025Q4 2024
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€0.20€0.20N/A€0.19€346.26 million€352.68 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Glaukos Co. stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Envista Holdings Co. stock logo
NVST
Envista
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
€0.060.27%N/A11.76%1 Years

Latest NVST, PEN, STVN, and GKOS Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/2/2025
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
annual€0.060.3%6/5/20256/5/20257/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Glaukos Co. stock logo
GKOS
Glaukos
0.19
5.54
4.71
Envista Holdings Co. stock logo
NVST
Envista
0.44
2.04
1.76
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.01
3.25
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.22
1.81
1.21

Institutional Ownership

CompanyInstitutional Ownership
Glaukos Co. stock logo
GKOS
Glaukos
99.04%
Envista Holdings Co. stock logo
NVST
Envista
N/A
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
N/A

Insider Ownership

CompanyInsider Ownership
Glaukos Co. stock logo
GKOS
Glaukos
5.80%
Envista Holdings Co. stock logo
NVST
Envista
1.30%
Penumbra, Inc. stock logo
PEN
Penumbra
4.20%
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
0.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Glaukos Co. stock logo
GKOS
Glaukos
78057.14 million51.61 millionOptionable
Envista Holdings Co. stock logo
NVST
Envista
12,700169.49 million169.95 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
3,90038.73 million36.59 millionOptionable
Stevanato Group S.p.A. stock logo
STVN
Stevanato Group
4,650302.84 million300.72 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Glaukos stock logo

Glaukos NYSE:GKOS

$96.22 -0.97 (-0.99%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$99.06 +2.84 (+2.95%)
As of 05/23/2025 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Envista stock logo

Envista NYSE:NVST

$16.73 -0.14 (-0.81%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$16.72 -0.02 (-0.11%)
As of 05/23/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products. This segment also provides software packages, which include DTX Studio Implant; DTX Studio Lab; and DTX Studio Clinic, a software package offered with its imaging products. It offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.

Penumbra stock logo

Penumbra NYSE:PEN

$268.72 +1.97 (+0.74%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$266.56 -2.16 (-0.80%)
As of 05/23/2025 06:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Stevanato Group stock logo

Stevanato Group NYSE:STVN

€22.24 -0.37 (-1.64%)
As of 05/23/2025 03:58 PM Eastern

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.